Monoclonal antibody | |
---|---|
Type | Whole antibody |
Target | interleukin 31 (IL-31) |
Clinical data | |
Trade names | Cytopoint |
Routes of administration | subcutaneous injection |
ATCvet code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII |
Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs. [1] It acts against interleukin 31 (IL-31), [2] which is a cytokine involved in causing itchiness (pruritus). [2] Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks. [3]
The United States Department of Agriculture (USDA) approved lokivetmab (manufactured by Zoetis and sold under the trade name Cytopoint) in December 2016, [3] and it was approved by the European Medicines Agency in 2017. [4] Lokivetmab was the first monoclonal antibody to be approved for use in animals in the European Union. [4]